Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.

BACKGROUND TNF inhibitors have revolutionized the treatment of psoriasis vulgaris as well as psoriatic and rheumatoid arthritis and Crohn disease. Despite our understanding that these agents block TNF, their complex mechanism of action in disease resolution is still unclear. OBJECTIVE To analyze globally the genomic effects of TNF inhibition in patients with psoriasis, and to compare genomic profiles of patients who responded or did not respond to treatment. METHODS In a clinical trial using etanercept TNF inhibitor to treat psoriasis vulgaris (n = 15), Affymetrix gene arrays were used to analyze gene profiles in lesional skin at multiple time points during drug treatment (baseline and weeks 1, 2, 4, and 12) compared with nonlesional skin. Patients were stratified as responders (n = 11) or nonresponders (n = 4) on the basis of histologic disease resolution. Cluster analysis was used to define gene sets that were modulated with similar magnitude and velocity over time. RESULTS In responders, 4 clusters of downregulated genes and 3 clusters of upregulated genes were identified. Genes downmodulated most rapidly reflected direct inhibition of myeloid lineage immune genes. Upregulated genes included the stable dendritic cell population genes CD1c and CD207 (langerin). Comparison of responders and nonresponders revealed rapid downmodulation of innate IL-1beta and IL-8 sepsis cascade cytokines in both groups, but only responders downregulated IL-17 pathway genes to baseline levels. CONCLUSION Although both responders and nonresponders to etanercept inactivated sepsis cascade cytokines, response to etanercept is dependent on inactivation of myeloid dendritic cell genes and inactivation of the T(H)17 immune response.

[1]  Clark,et al.  Possible importance of macrophage-derived mediators in acute malaria , 1981, Infection and immunity.

[2]  A. Palucka,et al.  TNF Skews Monocyte Differentiation from Macrophages to Dendritic Cells 1 , 2003, The Journal of Immunology.

[3]  D. Carlo,et al.  Persistence of T-cell clones in psoriatic lesions. , 1997, Archives of dermatology.

[4]  James G. Krueger,et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.

[5]  L. Old,et al.  Partial purification of a serum factor that causes necrosis of tumors. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Mcclanahan,et al.  IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. , 2006, The Journal of clinical investigation.

[7]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[8]  B. Rogala,et al.  Circulating Levels of Urokinase-Type Plasminogen Activator (uPA) and its Soluble Receptor (suPAR) in Patients with Atopic Eczema/Dermatitis Syndrome , 2006, Inflammation.

[9]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[10]  J. Steinke,et al.  The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. , 2008, The Journal of allergy and clinical immunology.

[11]  F. Nestle,et al.  From classical mouse models of psoriasis to a spontaneous xenograft model featuring use of AGR mice. , 2005, Ernst Schering Research Foundation workshop.

[12]  Stefan Jenisch,et al.  Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. , 2008, The Journal of investigative dermatology.

[13]  N. J. Eungdamrong,et al.  Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. , 2009, The Journal of investigative dermatology.

[14]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[15]  Chen Dong,et al.  CCR6 Regulates the Migration of Inflammatory and Regulatory T Cells1 , 2008, The Journal of Immunology.

[16]  M. Meurer,et al.  T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products , 1994, European journal of immunology.

[17]  G. D'Haens,et al.  Advances in biologic therapy for ulcerative colitis and Crohn’s disease , 2006, Current gastroenterology reports.

[18]  Reinhard Guthke,et al.  Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept , 2008, Arthritis research & therapy.

[19]  Pilar Romero,et al.  IL‐17‐producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17‐related cytokines , 2009, Journal of leukocyte biology.

[20]  J. V. van Meurs,et al.  Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis , 1999, Annals of the rheumatic diseases.

[21]  B. Weinshenker,et al.  Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. , 1989, Journal of the American Academy of Dermatology.

[22]  S. Chimenti,et al.  Identical TCR β-Chain Rearrangements in Streptococcal Angina and Skin Lesions of Patients with Psoriasis Vulgaris1 , 2006, The Journal of Immunology.

[23]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Wittkowski,et al.  Identification of Cellular Pathways of “Type 1,” Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis1 , 2008, The Journal of Immunology.

[25]  B. Nickoloff,et al.  What have we learned in dermatology from the biologic therapies? , 2006, Journal of the American Academy of Dermatology.

[26]  A. Gottlieb,et al.  A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis , 2007, Current medical research and opinion.

[27]  Hoffman Mk.  The effects of tumor necrosis factor on the production of interleukin-1 by macrophages. , 1986 .

[28]  A. Gottlieb.  Etanercept for the treatment of psoriasis and psoriatic arthritis , 2004, Dermatologic therapy.

[29]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[31]  R. Kastelein,et al.  Understanding the IL-23-IL-17 immune pathway. , 2006, Trends in immunology.

[32]  H. Cheroutre,et al.  More stories on Th17 cells , 2009, Cell Research.

[33]  R. Steinman,et al.  Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. , 2007, The Journal of clinical investigation.

[34]  G. Krueger,et al.  Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. , 2004, Archives of dermatology.

[35]  A. Gottlieb,et al.  An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis1 , 2006, The Journal of Immunology.

[36]  Lisa C. Zaba,et al.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses , 2007, The Journal of experimental medicine.

[37]  Robert Gentleman,et al.  An extensible application for assembling annotation for genomic data , 2003, Bioinform..

[38]  Mayte Suárez-Fariñas,et al.  Harshlight: a "corrective make-up" program for microarray chips , 2005, BMC Bioinformatics.